by support | Nov 28, 2022 | Uncategorized
NTM Info & Research Welcomes Attorney and Rare Disease Advocate, Candace Lerman to Board of Directors NTM Info & Research (NTMir) is pleased to announce the appointment of Candace Lerman, Esq. to the Board of Directors. Ms. Lerman is an attorney, consultant,...
by support | Nov 28, 2022 | Uncategorized
The Food and Drug Administration is convening a public workshop titled “Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis” on Wednesday, June 27th from 8:30pm to 4:30pm ET. The purpose of this workshop is...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research and the COPD Foundation is happy to announce the release of the Bronchiectasis and NTM Information Line: 1-833-411-LUNG (5864). The Bronchiectasis and NTM Information Line is a toll-free number managed by the C.O.P.D. Information Line for...
by support | Nov 28, 2022 | Uncategorized
Aradigm, the company that submitted Linhaliq to the FDA for approval, announced that they had received a complete response letter (CRL) from the FDA stating that they would not approve the treatment at this time. Many of you have communicated recently with the FDA...
by support | Nov 28, 2022 | Uncategorized
by Amy Leitman At the end of June I attended DIA 2016, the annual conference for the Drug Information Association, as part of their Patient Advocacy Fellowship Program. The Fellowship Program is a major initiative designed to build industry awareness of the...
